[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"JHM BioPharma (Tonghua) Co. , Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100611570","phase-3-efficacy-and-safety-of-recombinant-botulinum-toxin-type-a-eveotox-for-injection-in-the-treatment-of-adult-upper-limb-spasticity--100611570",false,"NCT07242300","Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .","A Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) in Adult Patients With Upper Limb Spasticity","Inclusion Criteria:\n\n* Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent\n* Participants with stable post-stroke Spasticity (ULS) for at least 3 months\n* Participants with Modified Ashworth Scale (MAS) score of at least 2 at elbow flexor or wrist flexor or finger flexor\n* Participants with DAS score of at least 2 on the Principal Target of Treatment (PTT) (one of four functional domains: dressing, hygiene, limb position and pain)\n* Participants who have been stable for at least 1 month prior to study entry in terms of oral antispasticity\n\nExclusion Criteria:\n\n* Previous use of any botulinum toxin within 6 months prior to screening, or plan to use any botulinum toxin during the study.\n* History of alcohol or drug abuse.\n* Known allergy or hypersensitivity to any component of the study products.\n* History of epilepsy\n* Known or suspected to be HIV positive, serologically positive for syphilis, or active hepatitis B or C\n* Any medical condition that may put the participant at increased risk for botulinum toxin type A use","ALL","18 Years","80 Years",{"count":20,"type":21},207,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a phase III clinical study to evaluate the efficacy and safety of recombinant botulinum toxin type A（Eveotox）in adult patients with upper limb spasticity. The purpose of this study was to observe efficacy and safety of Eveotox compared with placebo in adult patients with upper limb spasticity.",[27],"Upper Limb Spasticity (ULS)","NOT_YET_RECRUITING","2025-11-17",{"date":31,"type":32},"2025-11-21","ACTUAL",{"date":34,"type":21},"2026-01",{"date":36,"type":21},"2028-01",{"name":38,"class":39},"JHM BioPharma (Tonghua) Co. , Ltd.","NETWORK",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100588173","phase-3-efficacy-and-safety-of-recombinant-botulinum-toxin-type-a-eveotox-for-injection-to-treat-moderate-to-severe-glabellar-lines-100588173","NCT06937944","Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines","A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection (Eveotox) Compared With a Single Treatment of Botox and Placebo,and Repeated Treatment of Eveotox in Moderate to Severe Glabellar Lines","Inclusion Criteria:\n\n* Male or female subjects who are between 18 to 65 years of age\n* Moderate or severe glabellar lines during maximum frown based on the Investigator Global Assessment Frown Wrinkle Severity scale\n* Moderate or severe glabellar lines during maximum frown based on the Patient Frown Wrinkle Severity scale\n* Willing and able to follow all trial procedures, attend all scheduled visits, and successfully complete the trial\n\nExclusion Criteria:\n\n* Subjects who have a history of oversensitivity to the Botulinum Toxin A type or other components of the study drug\n* Subjects who have implanted any permanent materials in the glabellar area or received semi-permanent fillers within the first 2 years of screening\n* Subjects with active skin infections at the injection site or systemic skin disease, which the investigator judges can affect the evaluation of efficacy or safety\n* Subjects who have a history of injecting drugs similar to the study drug within 6 months prior to selection or are foreseen to use during the study period","65 Years",{"count":49,"type":21},669,[24],"This is a Phase 3 clinical study to evaluate the efficacy, safety, and immunogenicity of single\u002Frepeated injections of Eveotox in the treatment of moderate to severe glabellar lines. The study consists of Study Part 1 (randomized double-blind controlled study) and Part 2 (open-label study). Part I is a multicenter, randomized, double-blind, single-injection, active-controlled and placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of Eveotox in the treatment of moderate to severe glabellar lines; Part 2 is an open-label study to evaluate the efficacy, safety, and immunogenicity of repeated injections of Eveotox in the treatment of moderate to severe glabellar lines.",[53],"Moderate to Severe Glabellar Lines",[53],"RECRUITING","2025-08-25",{"date":58,"type":32},"2025-09-02",{"date":60,"type":32},"2025-04-30",{"date":62,"type":21},"2026-08",{"name":38,"class":39},15,""]